EQT Life Sciences Invests in Inhaled Asthma Therapy Developer Kinaset Therapeutics

EQT Life Sciences Invests in Inhaled Asthma Therapy Developer Kinaset Therapeutics

(IN BRIEF) EQT Life Sciences has invested in U.S.-based Kinaset Therapeutics as part of a USD 103 million oversubscribed Series B financing. The funding will support the clinical advancement of frevecitinib, a novel inhaled pan-JAK inhibitor designed to treat a broad population of asthma patients with unmet needs. As part of the investment, EQT Life Sciences’ Daniela Begolo will join Kinaset’s Board of Directors.

(PRESS RELEASE) STOCKHOLM, 12-Jan-2026 — /EuropaWire/ — EQT Life Sciences has invested in Boston-based Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing a novel inhaled therapy for the treatment of serious respiratory diseases. The investment was made through the LSP 7 Fund as part of Kinaset’s oversubscribed USD 103 million Series B financing round.

The funding round was led by RA Capital Management and Forge Life Science Partners, with participation from new investors including EQT Life Sciences, Vivo, Schroders, Willett Advisors, Pictet and Sixty Degree Capital. Existing investors Atlas Venture, 5AM Ventures and Gimv also took part. Proceeds from the financing will be used primarily to advance frevecitinib, Kinaset’s lead clinical program.

Frevecitinib is a differentiated, inhaled pan-JAK inhibitor designed to be delivered directly to the lungs via a single-capsule dry powder inhaler. The approach aims to achieve therapeutic concentrations in lung tissue while limiting systemic exposure, addressing a key limitation of many existing asthma treatments. The therapy is being developed for patients whose asthma remains inadequately controlled despite standard inhaled maintenance therapies.

Asthma affects millions of people worldwide, yet a substantial proportion of patients—particularly those with non-eosinophilic disease—do not respond sufficiently to current biologic or anti-inflammatory treatments. Kinaset’s strategy seeks to address this unmet need by combining validated JAK biology with an inhaled delivery format intended to broaden applicability across the asthma population.

As part of the investment, Daniela Begolo, Managing Director at EQT Life Sciences, will join Kinaset Therapeutics’ Board of Directors. EQT Life Sciences highlighted the company’s differentiated scientific approach and experienced management team as key factors underpinning the investment decision.

Kinaset plans to use the Series B proceeds to progress frevecitinib into a Phase 2 dose-ranging clinical study in patients with severe asthma, with the potential to explore additional respiratory indications in the future.

About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences aims to back the smartest inventors who have ideas that could truly make a difference for patients.

More information: www.eqtgroup.com/private-capital/eqt-life-sciences

About Kinaset Therapeutics, Inc. 
Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. With founding investors 5AM Ventures, Atlas Venture and Gimv, the Company is pursuing a patient-focused approach to build a leading respiratory therapeutics company.

See more information at the Company’s website

Media Contact:

EQT Press Office, press@eqtpartners.com

SOURCE: EQT